Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's
disease are needed to facilitate the initial screening process of participants in disease …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …

In the past years, neuroinflammation has been widely investigated in Alzheimer's disease
(AD). Evidence from animal, in vivo and post-mortem studies has shown that inflammatory …

Background and Objectives To determine whether CSF synaptic biomarkers are altered in
the early preclinical stage of the Alzheimer continuum and associated with Alzheimer …

INTRODUCTION Incorporating blood‐based Alzheimer's disease biomarkers such as tau
and amyloid beta (Aβ) into screening algorithms may improve screening efficiency …

Objective Elevated entorhinal cortex (EC) tau in low beta‐amyloid individuals can predict
accumulation of pathology and cognitive decline. We compared the accuracy of magnetic …

Objectives Accurately predicting when patients with mild cognitive impairment (MCI) will
progress to dementia is a formidable challenge. This work aims to develop a predictive deep …

Background: About 50 million people worldwide suffered from dementia in 2018—two-thirds
of those with Alzheimer's disease (AD). By 2050, this number is expected to rise to 152 …

Background Blood-based AD biomarkers such as plasma P-tau217 are increasingly used in
clinical trials as a screening tool. Objectives To assess the utility of an …